Kainulainen M, Harmon J, Karaaslan E, Kyondo J, Whitesell A, Twongyeirwe S
J Med Virol. 2024; 96(10):e29946.
PMID: 39370872
PMC: 11874798.
DOI: 10.1002/jmv.29946.
Zhang Y, Zhang M, Wu H, Wu X, Zheng H, Feng J
J Virol. 2024; 98(9):e0068524.
PMID: 39162435
PMC: 11406966.
DOI: 10.1128/jvi.00685-24.
Ilinykh P, Huang K, Gunn B, Kuzmina N, Kedarinath K, Jurado-Cobena E
Commun Biol. 2024; 7(1):871.
PMID: 39020082
PMC: 11255267.
DOI: 10.1038/s42003-024-06556-0.
Bagdonaite I, Abdurahman S, Mirandola M, Pasqual D, Frank M, Narimatsu Y
J Virol. 2024; 98(6):e0052424.
PMID: 38757972
PMC: 11237518.
DOI: 10.1128/jvi.00524-24.
Jackson H, Long H, Yam-Puc J, Palmulli R, Haigh T, Pereyra Gerber P
J Extracell Vesicles. 2024; 13(2):e12412.
PMID: 38339765
PMC: 10858312.
DOI: 10.1002/jev2.12412.
Translational success of fundamental virology: a VSV-vectored Ebola vaccine.
Anderson E, Coller B
J Virol. 2024; 98(3):e0162723.
PMID: 38305150
PMC: 10994820.
DOI: 10.1128/jvi.01627-23.
Direct enhancement of viral neutralising antibody potency by the complement system: a largely forgotten phenomenon.
Mellors J, Carroll M
Cell Mol Life Sci. 2024; 81(1):22.
PMID: 38200235
PMC: 10781860.
DOI: 10.1007/s00018-023-05074-2.
Protective mechanisms of nonneutralizing antiviral antibodies.
Chandler T, Yang A, Otero C, Permar S, Caddy S
PLoS Pathog. 2023; 19(10):e1011670.
PMID: 37796829
PMC: 10553219.
DOI: 10.1371/journal.ppat.1011670.
Antibodies against the Ebola virus soluble glycoprotein are associated with long-term vaccine-mediated protection of non-human primates.
Gunn B, McNamara R, Wood L, Taylor S, Devadhasan A, Guo W
Cell Rep. 2023; 42(4):112402.
PMID: 37061918
PMC: 10576837.
DOI: 10.1016/j.celrep.2023.112402.
Ebanga™: The most recent FDA-approved drug for treating Ebola.
Taki E, Ghanavati R, Navidifar T, Dashtbin S, Heidary M, Moghadamnia M
Front Pharmacol. 2023; 14:1083429.
PMID: 36969842
PMC: 10032372.
DOI: 10.3389/fphar.2023.1083429.
A high-throughput single-particle imaging platform for antibody characterization and a novel competition assay for therapeutic antibodies.
Seymour E, Unlu M, Connor J
Sci Rep. 2023; 13(1):306.
PMID: 36609657
PMC: 9821353.
DOI: 10.1038/s41598-022-27281-w.
Self-Assembled TLR7/8 Agonist-Mannose Conjugate as An Effective Vaccine Adjuvant for SARS-CoV-2 RBD Trimer.
Teng C, Meng X, Hu Y, Mao H, Li H, Yang J
Polymers (Basel). 2022; 14(24).
PMID: 36559833
PMC: 9785909.
DOI: 10.3390/polym14245466.
A platform technology for generating subunit vaccines against diverse viral pathogens.
Young A, Isaacs A, Scott C, Modhiran N, McMillan C, Cheung S
Front Immunol. 2022; 13:963023.
PMID: 36059532
PMC: 9436389.
DOI: 10.3389/fimmu.2022.963023.
Assays for the Evaluation of the Immune Response to Marburg and Ebola Sudan Vaccination-Filovirus Animal Nonclinical Group Anti-Marburg Virus Glycoprotein Immunoglobulin G Enzyme-Linked Immunosorbent Assay and a Pseudovirion Neutralization Assay.
Rudge Jr T, Machesky N, Sankovich K, Lemmon E, Badorrek C, Overman R
Vaccines (Basel). 2022; 10(8).
PMID: 36016099
PMC: 9413256.
DOI: 10.3390/vaccines10081211.
A Historical Review of Military Medical Strategies for Fighting Infectious Diseases: From Battlefields to Global Health.
Biselli R, Nisini R, Lista F, Autore A, Lastilla M, De Lorenzo G
Biomedicines. 2022; 10(8).
PMID: 36009598
PMC: 9405556.
DOI: 10.3390/biomedicines10082050.
Glycan shield of the ebolavirus envelope glycoprotein GP.
Peng W, Rayaprolu V, Parvate A, Pronker M, Hui S, Parekh D
Commun Biol. 2022; 5(1):785.
PMID: 35927436
PMC: 9352669.
DOI: 10.1038/s42003-022-03767-1.
Antibodies to combat viral infections: development strategies and progress.
Pantaleo G, Correia B, Fenwick C, Joo V, Perez L
Nat Rev Drug Discov. 2022; 21(9):676-696.
PMID: 35725925
PMC: 9207876.
DOI: 10.1038/s41573-022-00495-3.
Complement-Mediated Neutralisation Identified in Ebola Virus Disease Survivor Plasma: Implications for Protection and Pathogenesis.
Mellors J, Tipton T, Fehling S, Bore J, Koundouno F, Hall Y
Front Immunol. 2022; 13:857481.
PMID: 35493467
PMC: 9039621.
DOI: 10.3389/fimmu.2022.857481.
Structural basis for llama nanobody recognition and neutralization of HIV-1 at the CD4-binding site.
Zhou T, Chen L, Gorman J, Wang S, Kwon Y, Lin B
Structure. 2022; 30(6):862-875.e4.
PMID: 35413243
PMC: 9177634.
DOI: 10.1016/j.str.2022.03.012.
Therapeutic Strategies against Ebola Virus Infection.
Liu C, Hu Y, Wong S, Lin L
Viruses. 2022; 14(3).
PMID: 35336986
PMC: 8954160.
DOI: 10.3390/v14030579.